UPDATE: JP Morgan Cuts PT to $35 on Endo Health Solutions Ahead of Guidance

JP Morgan reiterated its Overweight rating on Endo Health Solutions ENDP and lowered its price target from #38 to $35. JP Morgan commented, "With no clear recovery in Opana ER prescriptions and following Endo's recent guidance updates, we are reducing our estimates and price target on ENDP shares. We see the company's 2013 guidance expected in January, further clarity on generic threats to the Opana franchise, and an upcoming CEO transition expected during the first half of the year as the most important near-term catalysts for the company." Endo Health Solutions closed at $26.03 on Wednesday.